返回
Vericiguat: First Approval
DOI:10.1007/s40265-021-01496-z.png)
摘要
En 中文
Vericiguat (VERQUVO (TM); Merck & Co, Bayer AG) is a soluble guanylate cyclase (sGC) stimulator being developed for the treatment of chronic heart failure. Vericiguat stimulates sGC and cGMP production independent of nitric oxide (NO) and enhances the effects of NO by stabilizing the NO-sGC binding. Based on the results of the phase III VICTORIA trial vericiguat was recently approved in the USA for risk reduction in patients with heart failure and ejection fraction < 45%. This article summarizes the milestones in the development of vericiguat leading to this first approval.
Keyword:
GUANYLATE-CYCLASE STIMULATOR
CHRONIC HEART-FAILURE
NATRIURETIC PEPTIDE
EJECTION FRACTION
AI总结
对已上传原文的论文进行重点信息的提取,主要内容包括:简要概述、研究摘要、背景介绍、关键亮点、图文解析、展望与总结。
期刊
IF:
14.4
论文数:
8.4K
被引数:
2.3W
机构
暂无机构信息
引用论文
Vericiguat in worsening heart failure: agonising over, or celebrating, agonism in the VICTORIA trial
CARDIOVASCULAR RESEARCH
IF13.3
Vericiguat in patients with worsening chronic heart failure and preserved ejection fraction: results of the SOluble guanylate Cyclase stimulatoR in heArT failurE patientS with PRESERVED EF (SOCRATES-PRESERVED) study
EUROPEAN HEART JOURNAL
IF35.6
没有更多内容

